Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

CD138: plasma cells are positive interstititally, <<5% of cellularity.
This bone marrow biopsy shows morphological evidence of a plasma cell infiltrate of <5% of cellularity, as confirmed on immunohistochemical staining.
Bone marrow haemopoietic reserve is mildly decreased.
C90.0 Multiple myeloma
M8000/3 Neoplasm, malignant, primary site

July 10
 · 
Be the first to react
MyMyelomaTeam

What do bone marrow biopsy results showing less than 5% plasma cell infiltrate, CD138 positive myeloma cells, and mildly decreased haemopoietic reserve mean after a stem cell transplant?

These results suggest the transplant is working well. Less than 5% plasma cell infiltrate is actually an encouraging sign — it means Show Full Answer

What do bone marrow biopsy results showing less than 5% plasma cell infiltrate, CD138 positive myeloma cells, and mildly decreased haemopoietic reserve mean after a stem cell transplant?

These results suggest the transplant is working well. Less than 5% plasma cell infiltrate is actually an encouraging sign — it means myeloma cells are present but at a very low level. Here's a plain-language breakdown of each finding:

- Less than 5% plasma cell infiltrate — A healthy bone marrow typically has fewer than 5% plasma cells. Being at or under this threshold post-transplant is a positive indicator of treatment response
- CD138 positive — CD138 is a marker used to identify plasma cells, including myeloma cells. Its presence helps doctors confirm and track any remaining myeloma activity
- Mildly decreased haemopoietic reserve — This means the bone marrow's ability to produce new blood cells is slightly reduced, which is common after high-dose chemotherapy and transplant

Doctors often monitor for minimal residual disease (MRD) after transplant — tiny numbers of remaining myeloma cells. These biopsy results help guide decisions about ongoing maintenance therapy.

It's really important to discuss these specific results with your oncologist, as they will interpret them in the full context of your treatment history and overall health.

July 10

Related Questions

View All